Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Denecimig · 1 trial · 1 indication
Measured as count of treated bleeds.
| Arm | Type | Description |
|---|---|---|
| Denecimig | EXPERIMENTAL | Denecimig will be administered subcutaneously. |
| Name | Type | Description |
|---|---|---|
| Denecimig | DRUG | Participants will receive subcutaneous (s.c.) injections of denecimig. |
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female participants (sex assigned at birth, inclusive of...
Denecimig is being developed for the treatment of haemophilia A, including acquired haemophilia A in adults. It is an investigational therapy being studied in a Phase 3 clinical trial in adults aged 18 years and older. It has not been established as an approved treatment.
Denecimig is being developed by Novo Nordisk A/S, which trades under the ticker NVO. The company is sponsoring the Phase 3 clinical program evaluating Denecimig in adults with acquired haemophilia A across multiple countries including the United States, United Kingdom, Germany, France, Japan, and others.
Denecimig is in Phase 3 clinical development. It is an investigational therapy and is not approved for commercial use. The ongoing Phase 3 study is currently recruiting participants and has an planned enrollment of 84 adults with acquired haemophilia A.
Denecimig is being evaluated in the Phase 3 trial NCT07830732, titled A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A. The trial is recruiting, has a planned enrollment of 84 participants, and is an uncontrolled study enrolling adults aged 18 years and older across 18 countries.
Yes, Denecimig is also known as Mim8. The Phase 3 trial NCT07830732 refers to the investigational therapy as Denecimig (Mim8), confirming that both names refer to the same Novo Nordisk development compound being studied in adults with acquired haemophilia A.